OncoC4
Rockville, Maryland, United States · Biotechnology · 66 employees
OncoC4 is a privately held, late-stage biopharmaceutical company engaged in the discovery and development of novel biologicals for treating cancer and immunological diseases. Its pipeline features assets with first-in-class and best-in-class potential. AI-081 is a potentially best-in-class bispecific antibody candidate currently enrolling patients in a Phase 1/2 trial. OncoC4 also has a collaborat
Funding history
- Series series b — $50.0M — Oct 2025
- Funding Round — Undisclosed — Jan 2021
Recent signals
- Oct 02, 2025: Raised $50.0M in Series series b
- Aug 18, 2025: OncoC4 Appoints Shiniu Wei as Chief Financial Officer
- Jan 07, 2021: Raised Undisclosed
See plans & pricing → Track OncoC4’s funding, hiring, and signals — with verified contacts — on Fundz.